Dow Chemical to acquire Rohm and Haas
This article was originally published in Scrip
Dow Chemicalhas reached a definitive agreement to acquire the speciality chemical company Rohm and Haasfor more than $15 billion, to create the world's leading speciality chemicals and advanced materials company. It will pay $78 in cash for each outstanding share, a more than 73% premium to Rohm and Haas's closing share price on July 9th. The move into more high-margin speciality chemicals should help protect Dow from the more cyclical basic chemical sales business, and it described it as a decisive move to transform Dow into an earnings growth company. Rohm and Haas is best known for its paint and electronics materials businesses but its technologies are found in a wide range of industries, including pharmaceuticals. The deal, which has been unanimously approved by the boards of both companies, remains subject to approval by Rohm and Haas shareholders and regulatory approvals.
You may also be interested in...
Biohaven’s investigational glutamate modulator troriluzole did not improve symptoms in patients with mild-to-moderate disease, adding to the list of failures in Alzheimer’s disease, as well as for the product itself.
The two companies can now market their HER-2 targeting antibody-drug conjugate in its second tumor type as they look to expand beyond breast cancer.
The Danish company pockets $40m as the lead asset in the potential multi-billion dollar deal with AbbVie for bi-specific antibodies progresses into Phase III, and while it looks to build up its commercial infrastructure.